Randall J.  Steward net worth and biography

Randall Steward Biography and Net Worth

CFO of QuidelOrtho
Randall J. Steward is the Chief Financial Officer at QuidelOrtho.

What is Randall J. Steward's net worth?

The estimated net worth of Randall J. Steward is at least $488,636.33 as of August 3rd, 2020. Mr. Steward owns 12,623 shares of QuidelOrtho stock worth more than $488,636 as of April 18th. This net worth approximation does not reflect any other investments that Mr. Steward may own. Learn More about Randall J. Steward's net worth.

How do I contact Randall J. Steward?

The corporate mailing address for Mr. Steward and other QuidelOrtho executives is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. QuidelOrtho can also be reached via phone at (800) 874-1517 and via email at [email protected]. Learn More on Randall J. Steward's contact information.

Has Randall J. Steward been buying or selling shares of QuidelOrtho?

Randall J. Steward has not been actively trading shares of QuidelOrtho over the course of the past ninety days. Most recently, Randall J. Steward sold 21,166 shares of the business's stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $286.31, for a transaction totalling $6,060,037.46. Following the completion of the sale, the chief financial officer now directly owns 12,623 shares of the company's stock, valued at $3,614,091.13. Learn More on Randall J. Steward's trading history.

Who are QuidelOrtho's active insiders?

QuidelOrtho's insider roster includes Michael Abney, Jr. (SVP), Douglas Bryant (CEO), William Ferenczy (SVP), Werner Kroll (SVP), Edward Michael (Director), Mary Polan (Director), Charles Slacik (Director), Randall Steward (CFO), and Matthew Strobeck (Director). Learn More on QuidelOrtho's active insiders.

Are insiders buying or selling shares of QuidelOrtho?

During the last year, QuidelOrtho insiders bought shares 1 times. They purchased a total of 2,150 shares worth more than $99,652.50. The most recent insider tranaction occured on February, 23rd when CFO Joseph M Busky bought 2,150 shares worth more than $99,652.50. Insiders at QuidelOrtho own 1.0% of the company. Learn More about insider trades at QuidelOrtho.

Information on this page was last updated on 2/23/2024.

Randall J. Steward Insider Trading History at QuidelOrtho

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/3/2020Sell21,166$286.31$6,060,037.4612,623View SEC Filing Icon  
5/18/2020Sell20,000$185.35$3,707,000.002,848View SEC Filing Icon  
9/23/2019Sell29,328$62.60$1,835,932.8048,787View SEC Filing Icon  
2/22/2019Sell39,103$67.50$2,639,452.5058,562View SEC Filing Icon  
12/3/2018Sell15,000$61.51$922,650.0016,790View SEC Filing Icon  
8/17/2018Sell38,162$70.15$2,677,064.3069,952View SEC Filing Icon  
12/12/2017Sell36,383$40.09$1,458,594.4756,290View SEC Filing Icon  
7/28/2017Sell94,215$34.09$3,211,789.3579,907View SEC Filing Icon  
See Full Table

Randall J. Steward Buying and Selling Activity at QuidelOrtho

This chart shows Randall J Steward's buying and selling at QuidelOrtho by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

QuidelOrtho Company Overview

QuidelOrtho logo
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $38.71
Low: $38.67
High: $40.35

50 Day Range

MA: $47.05
Low: $38.71
High: $69.54

2 Week Range

Now: $38.71
Low: $38.67
High: $95.02

Volume

754,587 shs

Average Volume

835,511 shs

Market Capitalization

$2.59 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.11